Back to Search Start Over

The Immune Landscape of Cancer

Authors :
Thorsson, Vésteinn
Gibbs, David L
Brown, Scott D
Wolf, Denise
Bortone, Dante S
Ou Yang, Tai-Hsien
Porta-Pardo, Eduard
Gao, Galen F
Plaisier, Christopher L
Eddy, James A
Ziv, Elad
Culhane, Aedin C
Paull, Evan O
Sivakumar, IK Ashok
Gentles, Andrew J
Malhotra, Raunaq
Farshidfar, Farshad
Colaprico, Antonio
Parker, Joel S
Mose, Lisle E
Vo, Nam Sy
Liu, Jianfang
Liu, Yuexin
Rader, Janet
Dhankani, Varsha
Reynolds, Sheila M
Bowlby, Reanne
Califano, Andrea
Cherniack, Andrew D
Anastassiou, Dimitris
Bedognetti, Davide
Mokrab, Younes
Newman, Aaron M
Rao, Arvind
Chen, Ken
Krasnitz, Alexander
Hu, Hai
Malta, Tathiane M
Noushmehr, Houtan
Pedamallu, Chandra Sekhar
Bullman, Susan
Ojesina, Akinyemi I
Lamb, Andrew
Zhou, Wanding
Shen, Hui
Choueiri, Toni K
Weinstein, John N
Guinney, Justin
Saltz, Joel
Holt, Robert A
Rabkin, Charles S
Cancer Genome Atlas Research Network
Lazar, Alexander J
Serody, Jonathan S
Demicco, Elizabeth G
Disis, Mary L
Vincent, Benjamin G
Shmulevich, Ilya
Source :
Immunity, vol 48, iss 4
Publication Year :
2018
Publisher :
eScholarship, University of California, 2018.

Abstract

We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we identified six immune subtypes-wound healing, IFN-γ dominant, inflammatory, lymphocyte depleted, immunologically quiet, and TGF-β dominant-characterized by differences in macrophage or lymphocyte signatures, Th1:Th2 cell ratio, extent of intratumoral heterogeneity, aneuploidy, extent of neoantigen load, overall cell proliferation, expression of immunomodulatory genes, and prognosis. Specific driver mutations correlated with lower (CTNNB1, NRAS, or IDH1) or higher (BRAF, TP53, or CASP8) leukocyte levels across all cancers. Multiple control modalities of the intracellular and extracellular networks (transcription, microRNAs, copy number, and epigenetic processes) were involved in tumor-immune cell interactions, both across and within immune subtypes. Our immunogenomics pipeline to characterize these heterogeneous tumors and the resulting data are intended to serve as a resource for future targeted studies to further advance the field.

Details

Database :
OpenAIRE
Journal :
Immunity, vol 48, iss 4
Accession number :
edsair.od.......325..d6df7f67e9b1e715f0a207f439f81d05